Loading
If a CDK4-only drug matches CDK4/6 inhibitors on efficacy with less neutropenia, continuous dosing and better adherence could translate into longer control.
The idea is to replace palbociclib, ribociclib and abemaciclib with a CDK4-selective drug such as atirmociclib, paired with letrozole, as the first-line backbone in HR-positive, HER2-negative breast cancer. Luminal breast cancer depends on cyclin D1 and CDK4, whereas CDK6 dependence is mainly haematopoietic, so sparing CDK6 should remove the neutropenia that forces dose holds and reductions with the current class. The hypothesis is non-inferior or superior progression-free survival with fewer severe blood-count events and higher dose intensity, so that continuous dosing and better adherence give longer control. FOURLIGHT-1 showed activity after CDK4/6 failure, and the enrolling phase 3 FOURLIGHT-3 trial is the test; the idea is at an early clinical stage.
This is the paper Europe PMC returns for registry id NCT01740427 with the most citations, so it is the natural first reading for anyone following the PALOMA-2 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT01958021 with the most citations, so it is the natural first reading for anyone following the MONALEESA-2 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
One of the most cited trial reports Europe PMC returns for Palbociclib in HR-positive / HER2-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Atirmociclib, Ribociclib, Abemaciclib, Palbociclib.
Shares Palbociclib and Letrozole in Advanced Breast Cancer, CDK4/6, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer, Ribociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares Ribociclib, Abemaciclib, Palbociclib.
Shares Ribociclib, Abemaciclib, Palbociclib.